The Food and Drug Administration has cleared bemotrizinol, a chemical UV filter long used in Europe and Asia, for U.S. sunscreens. Dermatologists applaud the move, noting the ingredient delivers broad‑spectrum protection on its own. The approval marks the first new sunscreen chemical in almost thirty years.

Bemotrizinol blocks both UVA and UVB rays while remaining photo stable. Unlike avobenzone, it does not break down quickly under sunlight, reducing irritation risk and maintaining efficacy beyond the typical two‑hour reapply window. Its larger molecular size limits skin absorption, addressing safety concerns raised over other U.S. filters.

DSM‑Firmenich spent $18 million over two decades to satisfy FDA’s stringent drug‑regulation criteria, earning exclusive U.S. rights for 18 months. The ingredient will appear under the brand Parsol Shield by September, promising clearer, non‑greasy formulas that avoid the white cast of zinc oxide.

With a robust safety record—animal studies show no reproductive harm and human trials confirm no irritation—bemotrizinol offers a practical solution to the current gap between effective UVA coverage and consumer compliance. Dermatologists now have a single, stable ingredient that could drive more frequent sunscreen use.